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5 A remarkable feature of P450 1A1/2 action is that the enzymes are highly inducible at both mRNA and enzyme levels by a range of chemicals (Whitlock, 1999; Ma, 2001) . Inducers in many cases are substrates of the enzymes such as benzo [a] pyrene (B[a] p) and 3-methylcholenthrene (3-MC). CYP1A1 is expressed at low levels in extrahepatic tissues in humans but is highly inducible in the liver and extrahepatic tissues.
CYP1A2 is constitutively expressed in the liver and is inducible. Induction of CYP1A by PAH is mediated through the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor. Binding of PAH to AhR elicits sequential signaling events leading to the activation of AhR and transcription of CYP1A genes through the dioxin response element (DRE) located in the enhancers of the genes. In this framework, PAH, AhR, DRE, and CYP1A1/2 form a receptor-mediated transcriptional loop that directly senses the concentrations of PAH in cells and increases the activities of the enzymes through transcription. Induction subsides as PAH is metabolized to ensure that induction is initiated and maintained only as needed. Therefore, induction is not only necessary for clearance of chemicals in the body but also tightly regulated according to the cellular concentrations of xenochemicals.
The biological impact of CYP1A induction can be two-fold. Induction of CYP1A in general serves as a means of maintaining the homeostasis of the chemical environment in cells by increasing the metabolic clearance of substrates. Since CYP1A1/2 catalyzes the metabolic activation of PAH and HAA to ultimate carcinogens, it is expected that induction of the enzymes is detrimental in humans that are exposed to high levels of PAH and HAA such as cigarette smoking. Moreover, induction of the enzymes in humans exhibits large variations (Ma and Lu, 2003) ; high inducibility may impose additional risk This article has not been copyedited and formatted. The final version may differ from this version. Because of the critical role of CYP1A in chemical carcinogenesis and toxicity, the implication of CYP1A induction in human risk evaluation has been and remains to be a central focus of interest in cancer research, drug development, toxicology, food safety, and environmental/occupational health since the discovery of CYP1A induction. In this review, we analyzed the evidence accumulated over the past five decades that implicates CYP1A induction in the biological effects of carcinogens, drugs, and environmental chemicals both as beneficial and detrimental responses. It is the authors' hope that such analysis would provide new insights into the human safety analysis of CYP induction and be instrumental to the application of in vitro and in vivo P450 reactions in human risk assessment.
II.
The discovery of CYP1A induction: initial observations of the impact of
CYP1A induction on cancer and toxicity
The discovery of CYP1A induction originates from the observation that PAH induces its own metabolism (Conney, 2003) . These early studies have also provided the initial in vivo evidence demonstrating large impacts of CYP1A induction on the toxicity and carcinogenesis of certain chemicals in animals. In 1952, Richardson and associates (Richardson et al., 1952) reported that co-administration of a strong hepatocarcinogen 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB) with a low dose of 3-methylcholanthrene (3-MC) in rats delayed or entirely inhibited liver tumor development (Miller et al., 1958) showed that the inhibition of carcinogenesis by 3-MC and other PAHs is not specific for 3'-Me-DAB, but also for tumorigenicity by aminoazo dyes, 2-acetylaminofluorene (AAF), and AAF derivatives.
A critical issue arises from these in vivo inhibition studies: what accounts for the protective effect of PAHs? To address the question, Conney et al (Conney et al., 1956) examined the effects of treating rats with 3-MC and other PAHs on the hepatic Ndemethylation and azo link reduction of aminoazo dyes, which are metabolic pathways resulting in noncarcinogenic products. The findings revealed that PAHs that inhibited aminoazo dye-induced liver cancer were potent inducers of azo dye N-demethylase, whereas those PAHs that did not affect azo dye-induced carcinogenesis had little or no effect on azo dye metabolism. This and subsequent other studies provided early evidence of CYP1A induction and a mechanistic explanation for the protective effect of PAHs on azo dye carcinogenesis (Conney, 2003) . The studies opened the gateway of research on CYP induction that had profound influence on the development of drug metabolism, cancer research, pharmacology, and toxicology over the following half century.
III. Mouse genetics in CYP1A induction.
Mouse genetics contributed greatly to the understanding of the mechanism of CYP1A induction. Induction was measured as an increase in the aryl hydrocarbon (Nebert and Gelboin, 1969; Kodama and Bock, 1970) . The sensitive phenotype was segregated as a single autosomal dominant trait (Gielen et al., 1972; Thomas et al., 1972) . The polymorphism of the genetic trait defines a genetic locus, which was designated as the Ah locus (aromatic hydrocarbon (C57BL/6), b-2 (C3H), and b-3 (Mus spretus) alleles (Poland et al., 1994) .
Among the inducers of CYP1A, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) was found to be the most potent for the induction of the enzymes. TCDD and 3-MC produce parallel log dose-response curves for the induction of AHH activity.
However, TCDD is about 30,000 times as potent as 3-MC (Poland and Glover, 1974) . In addition, induction by TCDD is persistent compared with that by PAH (>35 vs 8 days)
due to its long half life (t 1/2 = 17 days in rats); the symmetrical localization of chlorine atoms on the ring structure of TCDD gives rise to its resistance to metabolic breakdown and prolonged t 1/2 . Induction by TCDD and its congeners is stereospecific in structure.
While TCDD potently induces AHH with an ED 50 of 1 nmole/kg in responsive strains, the induction is also observed in all non-responsive strains with an ED 50 of about 10 nmoles/kg (Poland and Glover, 1975 (Niwa et al., 1975) . These observations suggest a diminished affinity for inducers in D2 mice as a cause of non-responsive phenotype in CYP1A induction by PAHs (Poland and Glover, 1975 The comparative studies on the potency and stereospecificity among the inducers and between the Ah responsive and non responsive strains for CYP1A induction, and later the demonstration of reversible, saturable, and high affinity binding of radio-labeled TCDD to a soluble cytoplasmic protein of hepatocytes, provided pharmacological evidence that the Ah locus product functions as an "induction receptor", designated as the aryl hydrocarbon receptor (AhR) (Poland and Glover, 1974; Poland and Glover, 1975; Poland et al., 1976) . In this regard, AhR binds a CYP1A inducer and mediates the induction of the genes.
In addition to CYP1A induction, "other biological effects" of CYP1A inducers, typified by TCDD, also segregate with the high affinity AhR genotype, implicating AhR in a broader range of biological effects of the inducers than CYP1A induction. These effects include a wasting syndrome, thymic involution, altered proliferation and differentiation of epithelial cells, endocrine disorders, and tumor promotion, which were collectively known as the "adverse response" of halogenated aromatic hydrocarbons (HAH) to reflect the fact that they were observed in animals treated with a single dose of TCDD and related halogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls (Poland and Knutson, 1982) . It is plausible to postulate that the "adverse response" requires high affinity and persistent binding leading to prolonged activation of AhR by TCDD. On the other hand, PAHs are rapidly metabolized by elevated CYP1A1 activity, and therefore a single dose of PAH is unable to sustain the activation of AhR to launch the "adverse response". In addition, TCDD and other HAHs are known to be metabolically resistant without forming reactive intermediates. Therefore, most of the effects of TCDD were thought to be mediated through AhR via an epigenetic mechanism(s).
This article has not been copyedited and formatted. The final version may differ from this version. The availability of mouse strains with high and low affinity AhRs provided a unique approach to the analysis of CYP1A induction and PAH carcinogenicity and toxicity (Nebert, 1989) (Table 1 ). In addition to differences in the sensitivity of the strains for both induction and toxicity by PAH, apparent disparities were observed in the (Table 1) .
The "Salmonella/liver enzymes" (or "Ames") test was employed to analyze the metabolic activation of 3-MC to mutagens with hepatic S-9 fractions from
mice . The findings revealed a correlation between induction of CYP1A1 enzyme activity and increased mutagenic activity of 3-MC. Many other PAHs were found to require bioactivation by CYP1A for their mutagenic effects in the "Ames" test as well, consistent with a linear mechanistic linkage among CYP1A induction, metabolic activation, mutagenesis, and tumorigenicity of PAHs.
The V79 Chinese hamster cell line contains the NADPH cytochrome P450
reductase but lacks P450-dependent activities. Genetic engineering of the cells with CYPs reconstitutes the metabolic capability thus permitting genotoxicity testing, in which mutagenic metabolites are both generated and detected in one cell type (Ellard et al., 1991 (Ellard et al., 1991) .
The 1970s were also marked with the elucidation of the chemical structures of the metabolites and the pathways of bioactivation of PAHs. More importantly, through the use of a combination of in vitro ("Ames" test, V79 culture, and rat microsome or P450 fractions) and in vivo assays, the trans-7,8-diol 9,10-epoxide metabolite of B[a]p was found to be the major metabolic product of the rat CYP1A1 enzyme and the principal ultimate mutagen and carcinogen of B[a]p (Conney, 1982; Jerina, 1983; Miller and Ramos, 2001) . From these studies, the concepts of pro, proximate, and ultimate carcinogens were developed. The studies also established the induction of the CYP1A1 enzyme activity as a primary event in the formation of the trans-7,8-diol 9,10-epoxide of hepatoma cell line that preserves many of the hepatocyte properties and is highly responsive to induction of CYP1A by PAH inducers (Whitlock, 1990; Hankinson, 1995 Conney and associates first revealed that AHH activity was detected in placentas obtained after birth from smoking mothers, but not from non-smokers, consistent with an induction of CYP1A by PAHs present in tobacco smoke (Welch et al., 1969) . However, AHH activities in placentas from mothers who smoke the same amount of cigarettes exhibit variations as large as 84-fold. In cultured neonatal human foreskin cells, basal AHH activities were detected with a 3-fold variability. The activity was inducible by benz[a]anthracene with a large variation (from 180 to 530%) among the testing individuals (Alvares et al., 1973) .
By using a mitogen-activated, PAH-treated human lymphocyte culture system, Kellermann et al (Kellermann et al., 1973a) observed that the normal white population in the United States can be divided into three distinct groups with low, intermediate, and
high degrees of inducibility of AHH activity. Phenotype frequencies were 53 percent, 37 percent, and 10 percent, respectively. Furthermore, by using the same assay, the same This article has not been copyedited and formatted. The final version may differ from this version. group found a close association between the susceptibility to bronchogenic carcinoma and high inducibility of AHH activity in 50 cancer patients (Kellermann et al., 1973b ).
These studies not only revealed large variations in the induction of CYP1A in human populations, but also suggest a causative role of CYP1A induction in the occurrence of cancer in certain human populations. Subsequent reports provided evidence supporting a correlation between high CYP1A inducibility and cancer of the lung, larynx, and oral cavity that are in direct contact with cigarette smoke. However, it is noteworthy to point out that no association between lung cancer and CYP1A inducibility has been reported in a number of studies (Ma and Lu, 2003) .
Together, from these early in vitro, mechanistic, and human studies, it appears to be logical to conclude that induction of CYP1A would impose detrimental effects upon individuals by way of metabolic activation of PAH and other chemicals to ultimate carcinogens or reactive toxic intermediates.
V. The Ah Receptor
A major obstacle to the study of the Ah receptor in the 1970s and 1980s was the difficulty in purifying the protein to homogeneity. By using 2-azido-3-[ 125 I]iodo-7,8-dibromodibenzo-p-dioxin, a photoaffinity ligand of AhR, Bradfield et al were able to covalently label the Ah receptor from the liver of C57BL/6J mice and purify the protein to apparent homogeneity under denaturing conditions. The purification procedure involved two ion exchange chromatography steps, which gave ~100 fold enrichment and 40-50% recovery, followed by three rounds of C4 reverse phase HPLC, to eventually reach a >150,000-fold purification with an overall yield of 3-5%. The putative amino-terminal sequence of the AhR peptide was determined from this This article has not been copyedited and formatted. The final version may differ from this version. . The antibodies also recognized AhR from chicken, rodents, monkey, and human, indicating conservation of the N-terminal epitope.
Cloning of the AhR cDNA (b-1 allele) using degenerate oligo probes derived from the putative N-terminal peptide sequence revealed that AhR contains 805 amino acid residues with a calculated molecular weight of 89,426 Dalton (Burbach et al., 1992) .
Importantly, the N-terminal region of AhR contains a stretch of basic residues followed by a helix-loop-helix turn motif; the structure is termed "bHLH" and is commonly seen among members of the bHLH family of transcription factors. The bHLH motif functions as the DNA-binding and protein dimerization domain of the transcription factors.
Additionally, the AhR protein contains two imperfect inverted 51-amino acid repeats adjacent to bHLH that were also found in Per, which is a circadian transcription factor, Arnt (aryl hydrocarbon receptor nuclear translocator), which is the dimeric partner of AhR for CYP1A transcription, and Sim, which is the Drosophila "single-minded"
protein. The motif was named as the "PAS" motif (Hoffman et al., 1991) . The "PAS" motif of AhR was found to involve ligand binding, binding with the hsp90 protein in the cytoplasm, and dimerization of AhR with Arnt in the nucleus. The carboxyl half of AhR contains three separable transcription activation domains that are acidic, serine/threoninerich, and glutamine-rich, respectively (Ma et al., 1995) . Thus, AhR was formally classified as a ligand-activated transcription factor of the bHLH-PAS family.
This article has not been copyedited and formatted. The final version may differ from this version. The human AhR is about 10-fold less sensitive to the induction of AHH activity by TCDD than that of B6 AhR in parallel with a 10-fold lower binding affinity for TCDD, resembling the Ah non-responsive phenotype (Harper et al., 1988) . Cloning of the human AhR cDNA revealed that it encodes a protein of 848 amino acid residues (Ema et al., 1994) . Structurally, the human AhR is more similar to the D2 AhR than the B6 AhR with two critical determinants reducing ligand binding affinity observed in D2
AhR: a T to G mutation at the position equivalent to the termination codon (TGA) of the B6 (Okey et al., 1989) .
VI. The CYP1A knockout mouse models
The construction of targeted knockout mouse models of the cyp1a1, cyp1a2, cyp1b1, and double knockout of the genes made it possible to directly evaluate the role of CYP1A in chemical toxicity and carcinogenesis in intact animals. Distinctly contradictory to the observations from in vitro studies that CYP1A enhances the toxicity of PAHs, the intact animal experiments after oral dosing revealed an essential protective role of CYP1A induction in PAH toxicity (Table 1 ). (Snyderwine et al., 2002; Kimura et al., 2003 ). The results demonstrate alternative pathways of metabolic activation of ABP, IQ, and PhIP in the absence of CYP1A2 and protection against adduct formation of the chemicals by CYP1A2 in intact animals.
The more "stable" ligands of AhR, exemplified by TCDD, can cause a broad range of "adverse response" in animals in an AhR-dependent manner in addition to CYP1A induction. The mechanism of the toxic effects of TCDD is not well understood.
TCDD is a poor substrate of CYP1A and does not form reactive intermediates. The interrelation between CYP1A induction and TCDD toxicity remains a subject of debate.
The teratogenic effect of TCDD (cleft palate formation and hydronephrosis) was assessed
, and cyp1b1 -/-mice . TCDD at 25 µg/kg by gavage on gestation day 10 was found to be lethal to fetuses carried by cyp1a2 -/-, but not 
VII. The omeprazole story
Omeprazole (brand name: Prilosec, Rapinex) is a proton pump (H + , K + -ATPase)
inhibitor used for its high efficiency as a blocker of gastric acid secretion in gastric parietal cells. Omeprazole is used clinically for the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD), and the ZollingerEllison syndrome. A major pathway of metabolism of omeprazole is its conversion to 5-hydroxy-omeprazole by CYP2C19 (Andersson, 1996) . Metabolism to 5-O-desmethylomeprazole by CYP2C19, and to 3-hydroxy-omeprazole and omeprazole sulfone by CYP3A constitutes the minor metabolic pathways of the drug.
Although omeprazole is not a substrate of CYP1A, it induced CYP1A1/2 in primary human hepatocytes at mRNA, protein, and enzyme (phenacetin deethylase, acetanilide hydroxylase, benzpyrene hydroxylase, and ethoxyresorufin deethylase) levels (Diaz et al., 1990) . Induction of the CYP1A2 protein was from 4 to 50 fold, comparable to induction by 3-MC or β-naphthoflavine (βNF) in cultured human hepatocytes.
Moreover, 2 to 10 fold induction of the CYP1A2 protein and CYP1A-dependent activities was observed in vivo in liver biopsies from cancer patients before and after 4 day-treatment with omeprazole at therapeutic doses. The study established omeprazole as the first clinical drug to be characterized as an inducer of CYP1A in the human liver (Diaz et al., 1990 ). (Sohn et al., 1992; Chiba et al., 1993) . Differences in the rate of 5-hydroxylation between poor metabolizers (PM) and extensive metabolizers (EM) results in different tissue levels of omeprazole available for CYP1A induction (Tang et al., 2005) . At a therapeutic dose (40 mg), omeprazole failed to induce CYP1A2 as measured by a caffeine N-3-demethylation breath test in individuals with EM phenotype, but the induction was revealed at a higher dose (120 mg) in the same individuals. On the other hand, induction of CYP1A2 by omeprazole was observed in individuals with PM phenotype at the dose of 40 mg. Clearly, individual variations in the metabolic rate of omeprazole affect the intracellular concentration of the inducer contributing to variability of CYP1A induction (Rost et al., 1992; Rost et al., 1994) .
In several clinical studies, induction of CYP1A2 by omeprazole was examined using CYP1A2 marker drugs (caffeine and phenacetin) in human volunteers who were not phenotyped for CYP2C19. Induction of caffeine and phenacetin metabolism by CYP1A2 was not observed (Andersson et al., 1991; Xiaodong et al., 1994; Rizzo et al., 1996) . It is noteworthy that these studies were conducted in White populations, in which only a small portion of the population are PM, while most individuals are EM.
Therefore, induction of CYP1A can not be observed with 40 mg of omeprazole in these populations. Cancer patients in general have a decreased capacity of drug metabolism; therefore, many of them represent PM subjects. This notion may explain why marked induction of CYP1A by omeprazole was observed in the study of cancer patients by Diaz and associates discussed above (Diaz et al., 1990 ).
This article has not been copyedited and formatted. The final version may differ from this version. Since CYP1A2 is the major phenacetin deethylase in humans, induction of the enzyme by omeprazole would increase the metabolism of phenacetin to acetaminophen and further to the formation of N-acetyl-p-benzoquinoneimine that is responsible for liver necrosis induced by the drugs. Based on this knowledge, it can be argued (Farrell and Murray, 1990 ) that acetaminophen liver toxicity could be increased in patients receiving both omeprazole and phenacetin or acetaminophen (two widely used analgesic drugs). resulting in decreased carcinogenicity of the compound (Koser et al., 1988 
VIII. CYP1A induction and drug development
The realization of the prominent role of inducible CYP1A1 in the metabolic activation of PAHs and that of CYP1A2 in the activation of HAA, phenacetin and other drugs led to a widely held belief that induction of CYP1A is detrimental to humans and animals in general. This notion had a broad impact on chemical safety evaluation, in particular, in the area of carcinogenesis and environmental health. The role of CYP1A induction in drug development remains debatable and warrants certain clarification.
In two recent publications concerning CYP1A induction, it was stated that pharmaceutical companies employ a general policy for several decades that, in routine drug development testing, if a candidate drug shows CYP1 inducibility, further testing is generally discontinued for fear of possible toxic or carcinogenic effects Uno et al., 2004) . However, the two references cited to support this argument apparently did not address CYP1 induction as a general policy in drug screening (Valles et al., 1995; Gastel, 2001) . There is a lack of supporting evidence for the statement in literature as well.
It is our understanding that, although potential induction of drug-drug interaction and bioactivation of toxic or carcinogenic compounds due to the induction of CYP1A1/1A2 have been a concern of safety in drug development, induction of CYP1A was rarely the deciding factor to determine whether a compound should be dropped for further testing because of its inducibility of CYP1A. In fact, omeprazole has been shown to be a CYP1A2 inducer both in cultured human hepatocytes and in the human liver This article has not been copyedited and formatted. The final version may differ from this version. (Diaz et al., 1990 ). Yet it was approved by Regulatory Agencies worldwide and has been used safely for more than 20 years by millions of people for clinical treatment of gastric ulcer and related disorders.
In the practice of drug development, it is recognized that induction of CYP1A2
can affect the drug level of co-administered drugs that are metabolized by CYP1A2. The issue is treated like the induction of other P450 enzymes such as CYP3A4. Drug-drug interactions can be evaluated by in vitro metabolism studies, and by clinical DDI studies.
The drug candidate is only dropped if it has very serious safety issues and clinically relevant DDI effects.
The clinical use of omeprazole provided an example of cancer risk evaluation of CYP1A inducers in drug development (Farrell and Murray, 1990) . The CYP1A inducibility of omeprazole in humans and its inter-individual variability associated with CYP2C19 phenotypes were well documented. Increased risk of malignancy in patients taking omeprazole is theoretically possible due to the critical role of CYP1A in the metabolic activation of PAH and other carcinogens. On the basis of these considerations, it was suggested that patients for whom long-term administration of omeprazole is highly desirable should minimize exposure to cigarette smoke and dietary sources of PAHs such as charboiled food and continued long-term surveillance of such individuals for potential increase of malignancy was recommended (Farrell and Murray, 1990) . However, the results from knockout mice and the safety record of omeprazole used by millions of individuals in over twenty years have not yet shown an etiological connection between omeprazole use and cancer incidence.
IX. Conclusion
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
Similar to d/d
Profound toxicity and death similar to d/d a Summarized from a number of references (Robinson et al., 1975; Nebert and Jensen, 1979; Conney, 1982; Nebert, 1989; Whitlock, 1999; Uno et al., 2004; Uno et al., 2006 
